EWSR1 and neoplasm: Mechanistically, YK-4-279 (and presumably TK-216) binds directly with the pathognomonic fusion-mediate chimeric transcription factor and tumor maintenance driver EWS-FLI118–21 to inhibit its interaction with RNA helicase A (RHA)22.